H1B Salary Data

Home › Employers › Southeast Retina Center PC

Southeast Retina Center PC: H-1B salaries and sponsorship

Southeast Retina Center PC filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: $117,618.

Applications (LCAs)3
Certified2
Employer addressAugusta, GA
H-1B dependent employerNo
Median offered salary$117,618
Middle half of salaries$113,809–$121,426
10th–90th percentile$111,524–$123,712

Does Southeast Retina Center PC sponsor H-1B visas?

Southeast Retina Center PC filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 10, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Biochemist/Clinical Research Director2$125,235
Biochemist/Clinical Research Manager1$110,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20231$110,000
FY20262$125,235

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Biochemist/Clinical Research Director$125,235
Level III
Augusta, GAApr 10, 2026Jul 13, 2026Certified
Biochemist/Clinical Research Director$125,235
Level III
Augusta, GAApr 10, 2026Jul 13, 2026Withdrawn
Biochemist/Clinical Research Manager$110,000
Level IV
Augusta, GAMar 21, 2023Jul 13, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).